甲状旁腺功能减退症:从实验室到临床的转化科学
本综述整合了甲状旁腺功能减退症在诊断、PTH类似物、钙敏感受体调节剂、临床前治疗药物、甲状旁腺组织移植及多能干细胞治疗等方面的最新进展。长效PTH类似物和钙敏感受体负向变构调节剂等靶向治疗可减少对活性维生素D和钙剂的需求,再生医学方法为未来治愈性治疗提供了平台。转化研究正推动甲状旁腺功能减退症管理向恢复更生理性矿物质稳态的方向转变。
要点
- 长效PTH类似物可持续激活PTH受体,减少活性维生素D和钙剂需求。
- 钙敏感受体负向变构调节剂可纠正常染色体显性低钙血症1型的受体过度激活。
- 靶向基因检测、甲状旁腺自身免疫检测和即时钙监测有助于个体化实时管理。
核心结论
- 转化研究正重新定义甲状旁腺功能减退症的管理,向恢复更生理性矿物质稳态转变。
研究设计与样本
- 综述整合了甲状旁腺功能减退症诊断、PTH类似物、钙敏感受体调节剂、临床前治疗药物、甲状旁腺组织移植及多能干细胞治疗等领域的最新发现。
主要发现
- 长效PTH类似物(如palopegteriparatide、eneboparatide和canvuparatide)显示持续激活PTH受体,减少对活性维生素D和钙剂的需求。
- 钙敏感受体负向变构调节剂(如encaleret)可纠正常染色体显性低钙血症1型患者的钙敏感受体过度激活,并可能扩展至其他类型甲状旁腺功能减退症。
- 多能干细胞甲状旁腺再生生物学进展为未来治愈性治疗提供了平台。
- 甲状旁腺自体移植、同种异体移植和移植物保存策略的进展进一步拓展了治疗格局。
- 新兴诊断技术包括靶向基因检测、甲状旁腺自身免疫检测和即时钙监测,可能实现个体化实时管理。
临床怎么用
- 长效PTH类似物和钙敏感受体负向变构调节剂等靶向治疗有望减少活性维生素D和钙剂补充需求。
- 新兴诊断技术可能支持甲状旁腺功能减退症的个体化和实时管理。
- 再生医学和移植策略的进展为未来治愈性治疗提供了方向。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Chronic hypoparathyroidism is a rare endocrine disorder characterised by hypocalcaemia due to insufficient parathyroid hormone (PTH) that is associated with a multidimensional reduced quality of life, impairing physical and cognitive functioning, and compromising emotional, psychological, and social wellbeing. This Review integrates recent findings on hypoparathyroidism diagnosis, PTH analogues, calcilytics, preclinical therapeutic agents, parathyroid tissue transplantation, and pluripotent stem cell-based therapies. Emerging diagnostic technologies, including targeted genetic testing, parathyroid autoimmunity assays, and point-of-care calcium monitoring, could enable individualised and real-time management. PTH analogues with extended action (eg, palopegteriparatide, eneboparatide, and canvuparatide) show sustained activation of PTH receptors with reduced requirements for active forms of vitamin D and calcium supplements. Calcilytics (eg, encaleret) normalise calcium-sensing receptor (CaSR) hyperactivation in patients with autosomal dominant hypocalcaemia type 1 and have the potential for broader application in other forms of hypoparathyroidism. Advances in parathyroid regenerative biology with pluripotent stem cells provide platforms for future curative therapies. Progress in parathyroid autotransplantation, allotransplantation, and graft-preservation strategies further expands the therapeutic landscape. Translational research is redefining the future of hypoparathyroidism management. Developments in receptor-targeted therapies, long-acting PTH analogues, negative allosteric modulators of CaSR, and regenerative approaches reflects a shift towards restoring mineral homoeostasis to a more physiological state.
引用
- Brandi ML, AbuAlrob H, Chang W, et al. Hypoparathyroidism: translating science from the laboratory to the clinic. Lancet Diabetes Endocrinol. 2026. PMID: 42705258. doi:10.1016/S2213-8587(26)00188-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。